InvestorsObserver
×
News Home

Is Turning Point Therapeutics Inc (TPTX) the Top Pick in the Biotechnology Industry?

Monday, October 12, 2020 12:07 PM | InvestorsObserver Analysts

Mentioned in this article

Is Turning Point Therapeutics Inc (TPTX) the Top Pick in the Biotechnology Industry?

Turning Point Therapeutics Inc (TPTX) is near the top in its industry group according to InvestorsObserver. TPTX gets an overall rating of 64. That means it scores higher than 64 percent of stocks. Turning Point Therapeutics Inc gets a 78 rank in the Biotechnology industry. Biotechnology is number 27 out of 148 industries.

Overall Score - 64
TPTX has an Overall Score of 64. Find out what this means to you and get the rest of the rankings on TPTX!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 64 would rank higher than 64 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Turning Point Therapeutics Inc Stock Today?

Turning Point Therapeutics Inc (TPTX) stock is trading at $121.08 as of 11:51 AM on Monday, Oct 12, a gain of $9.27, or 8.29% from the previous closing price of $111.81. The stock has traded between $113.22 and $121.91 so far today. Volume today is 388,776 compared to average volume of 403,050.

Click Here to get the full Stock Score Report on Turning Point Therapeutics Inc (TPTX) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App